Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival.

<h4>Background</h4>Circulating autoantibodies occur more frequently in cancer patients than in patients without cancer.<h4>Methods and findings</h4>We examined sera from patients referred for pelvic mass symptoms to a tertiary university clinic. A total of 127 were diagnosed...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Niels H H Heegaard, Mikkel West-Nørager, Julia T Tanassi, Gunnar Houen, Lotte Nedergaard, Claus Høgdall, Estrid Høgdall
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2c3304315d514daba24c5dbedd9d2395
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2c3304315d514daba24c5dbedd9d2395
record_format	dspace
spelling	oai:doaj.org-article:2c3304315d514daba24c5dbedd9d23952021-11-18T07:27:42ZCirculating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival.1932-620310.1371/journal.pone.0030997https://doaj.org/article/2c3304315d514daba24c5dbedd9d23952012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22363532/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Circulating autoantibodies occur more frequently in cancer patients than in patients without cancer.<h4>Methods and findings</h4>We examined sera from patients referred for pelvic mass symptoms to a tertiary university clinic. A total of 127 were diagnosed with epithelial ovarian cancer while 386 had a benign condition. A screen for IgG anti-nuclear antibodies (ANA) by indirect immunofluorescence on HEp-2 cells confirmed a highly significant overrepresentation of ANA in the cancer group where 40% had detectable (i.e., a titer ≥160) ANA compared with less than 12% in the benign group. The overrepresentation of ANA in the cancer group persisted (p<0.0001) after matching the age-profile of the benign group with the ovarian cancer group. Only 19 out of 127 patients in the age-matched benign subgroup were positive for ANA corresponding to an 85% specificity at 40% sensitivity of ANA as the only marker for malignancy. No correlation of ANA positivity in either group with specific bands in immunoblots could be demonstrated even though immunoblot positivity was clearly increased in the malignant group (41% vs. 3%). The presence, strength, and type of ANA did not correlate with serum CA-125 values or with staging, and ANA outcome did not contribute with independent diagnostic information. However, survival was significantly shorter in ANA-positive compared with ANA-negative cancer patients and patients with CA-125 below the median CA-125 value in the cancer group had a significantly decreased survival when positive for ANA. ANA status made no difference in the group with CA-125 values above the median. Also, there was a significant correlation between speckled ANA-strength and histological tumor grade.<h4>Conclusions</h4>Circulating antibodies are a promising source for new biomarkers in cancer. Characterization of epitope specificities and measurements of consecutive samples will be important for further elucidating the role of ANA in evaluating ovarian cancer patients.Niels H H HeegaardMikkel West-NøragerJulia T TanassiGunnar HouenLotte NedergaardClaus HøgdallEstrid HøgdallPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 2, p e30997 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Niels H H Heegaard Mikkel West-Nørager Julia T Tanassi Gunnar Houen Lotte Nedergaard Claus Høgdall Estrid Høgdall Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival.
description	<h4>Background</h4>Circulating autoantibodies occur more frequently in cancer patients than in patients without cancer.<h4>Methods and findings</h4>We examined sera from patients referred for pelvic mass symptoms to a tertiary university clinic. A total of 127 were diagnosed with epithelial ovarian cancer while 386 had a benign condition. A screen for IgG anti-nuclear antibodies (ANA) by indirect immunofluorescence on HEp-2 cells confirmed a highly significant overrepresentation of ANA in the cancer group where 40% had detectable (i.e., a titer ≥160) ANA compared with less than 12% in the benign group. The overrepresentation of ANA in the cancer group persisted (p<0.0001) after matching the age-profile of the benign group with the ovarian cancer group. Only 19 out of 127 patients in the age-matched benign subgroup were positive for ANA corresponding to an 85% specificity at 40% sensitivity of ANA as the only marker for malignancy. No correlation of ANA positivity in either group with specific bands in immunoblots could be demonstrated even though immunoblot positivity was clearly increased in the malignant group (41% vs. 3%). The presence, strength, and type of ANA did not correlate with serum CA-125 values or with staging, and ANA outcome did not contribute with independent diagnostic information. However, survival was significantly shorter in ANA-positive compared with ANA-negative cancer patients and patients with CA-125 below the median CA-125 value in the cancer group had a significantly decreased survival when positive for ANA. ANA status made no difference in the group with CA-125 values above the median. Also, there was a significant correlation between speckled ANA-strength and histological tumor grade.<h4>Conclusions</h4>Circulating antibodies are a promising source for new biomarkers in cancer. Characterization of epitope specificities and measurements of consecutive samples will be important for further elucidating the role of ANA in evaluating ovarian cancer patients.
format	article
author	Niels H H Heegaard Mikkel West-Nørager Julia T Tanassi Gunnar Houen Lotte Nedergaard Claus Høgdall Estrid Høgdall
author_facet	Niels H H Heegaard Mikkel West-Nørager Julia T Tanassi Gunnar Houen Lotte Nedergaard Claus Høgdall Estrid Høgdall
author_sort	Niels H H Heegaard
title	Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival.
title_short	Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival.
title_full	Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival.
title_fullStr	Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival.
title_full_unstemmed	Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival.
title_sort	circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/2c3304315d514daba24c5dbedd9d2395
work_keys_str_mv	AT nielshhheegaard circulatingantinuclearantibodiesinpatientswithpelvicmassesareassociatedwithmalignancyanddecreasedsurvival AT mikkelwestnørager circulatingantinuclearantibodiesinpatientswithpelvicmassesareassociatedwithmalignancyanddecreasedsurvival AT juliattanassi circulatingantinuclearantibodiesinpatientswithpelvicmassesareassociatedwithmalignancyanddecreasedsurvival AT gunnarhouen circulatingantinuclearantibodiesinpatientswithpelvicmassesareassociatedwithmalignancyanddecreasedsurvival AT lottenedergaard circulatingantinuclearantibodiesinpatientswithpelvicmassesareassociatedwithmalignancyanddecreasedsurvival AT claushøgdall circulatingantinuclearantibodiesinpatientswithpelvicmassesareassociatedwithmalignancyanddecreasedsurvival AT estridhøgdall circulatingantinuclearantibodiesinpatientswithpelvicmassesareassociatedwithmalignancyanddecreasedsurvival
_version_	1718423397516443648

Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival.

Ejemplares similares